smile, are you kidding me, stop posting those childish videos, ECYT spending 10 million dollars a Q, it is bleeding ... your money.
smart people, any good stocks out there. again, I'm a bottom fisher, do not suggest expensive stocks. I'm looking for hidden gems. I have 350K to invest.
Do not be ignorant and follow bakers brothers in every move. I made few hundreds in XOMA, bakers last their pant on that one after I sold. Bakers burn the bread sometimes. In the case of ECYT they lost since they bought, also that is old news before 9/30. may be they sold their stocks already.
Is this new year resolution, smile. People exercise or diet or love. you post meaningless messages. By the way I'm not short or long on this stock.
I love your excitement about ECYT. It seems that you have positive answer for all comments, but I have a quick question for you, can you tell me why the stock is trading at $3.91 with 10% shorts on it. It looks like no one knows this news about ECYT but you, with do respect. Also, why insiders are not buying the stock, it is at cash value and the pipeline is free. MM also selling now, very scary, they know more than others!! I hope ECYT do well, as I profited very good from the stock and they are working on noble medicine if it succeed. I still believe this company needs an outside agency to evaluate and clean the pipeline.
I was an investor of ECYT back in 2012. I bought 14,000 shares at an average of $5, sold a little early at $11. I have seen it climb to more than $30 and now back to $3.95 after their ovarian medication failure. Now what, well, it does not look good, they are burning cash at more than 10 million a Q, and it will accelerate as they are getting in more trials and later phase trials. MRK pulled out of the deal! but they are still on the same course. That tells me there are some idiots in the companies who do not tell sh.t from Shinola. Someone need to get there and stop the bleeding by evaluating the pipeline and figure out if there is still anything worth pursuing, Im sure there is 20% of a value. Then use the cash to develop it and focus the effort. Otherwise we will see this stock inching slowly and firmly to bankruptcy , Zero value. I have seen it in may stocks before. Good luck both longs and shorts. Remember in the next couple days are tax selling that will bleed it even more.
Euro Pacific Canada has upgraded Sophiris Bio (NASDAQ:SPHS) to “buy” from “hold” and raised its price target to $6 from $1 after the company reported positive one-year efficacy data from a Phase 3 study of PRX-302 in benign prostatic hyperplasia (BPH).
buy3Shares of Sophiris closed at $2.90 on Tuesday after jumping $2.04 on the news.
Analyst Doug Loe writes that not only was the study a positive data point, “but particularly so when considering the multiple Phase 3 failures experienced by Sophiris’ BPH drug development peers in recent years, making the achievement of generating a positive Phase 3 efficacy signal in this difficult-to-treat medical market even more compelling.”
The key takeaway is that “we have heightened confidence in PRX-302’s approvability in the difficult-to-treat BPH market,” he added.
Mr. Loe also said the long-term efficacy in the PLUS-1 study from only a single intra-prostatic injection at enrollment is hugely positive for PRX-302’s medical and commercial prospects.
Street Watchdog Research initiated coverage on Sophiris Bio (NASDAQ: SPHS) with a Buy rating and $7.50 price target. Link
From the report: "Our due diligence suggests that Sophiris has more than enough financial resources to fund operations with no additional share issuances through its next Phase III trial.
Given the substantial size of the benign prostatic hyperplasia (BPH or enlarged prostate) market, we estimate peak sales over $700 million. We believe the company will achieve a favorable outcome in its 2nd Phase III trial, which we expect to have a reduced trial completion time. As such, we are buyers of Sophiris."
The firm said it is long the stock.